X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-MarketGlobeNewsWire • 05/16/23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/04/23
X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023GlobeNewsWire • 04/26/23
X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome studyProactive Investors • 04/12/23
X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)GlobeNewsWire • 04/12/23
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/21/23
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023GlobeNewsWire • 03/07/23
X4 Pharmaceuticals' Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic NeutropeniaGlobeNewsWire • 12/12/22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM SyndromeGlobeNewsWire • 11/29/22
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory BoardBusiness Wire • 11/07/22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/03/22
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial OfficerGlobeNewsWire • 10/26/22
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022GlobeNewsWire • 10/20/22
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN)GlobeNewsWire • 09/27/22
X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic NeutropeniaGlobeNewsWire • 08/31/22